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Arbutin, (4‑hydroxyphenyl‑β‑D‑glucopyranoside), the 
β‑glucoside of hydroquinone (fig. 1), is present in 
several plants[1] and has mainly an antiseptic action 
on urinary tract[2]. Arbutin is the main constituent of 
Arctostaphylos uva‑ursi (L.) Spreng (Ericaceae), a 
medicinal plant known as bearberry, and in the market 
many phytotherapeutic products, made with its leaves, 
are present and are widely used to treat a variety of 
urinary disorders, such as urinary tract infections, 
inflammatory conditions of the efferent urinary tract, 
cystitis, urethritis, diuresis, lithuria, dysuria, acidic 
urine, pyelonephritis, kidney stones[3‑5].
Arbutin is generally present in plants in combination 
with methylarbutin, especially in those belonging to 
the Ericaceae family[2]. It has been observed that in 
physiological conditions, after oral ingestion arbutin 
is absorbed by the gastrointestinal tract, it reaches the 
liver and then it is hydrolyzed to hydroquinone, which 
is finally conjugated to sulphuric and glucuronic acid 
by phase II enzymatic system.
The 64‑75% of orally ingested arbutin is excreted 
in urine as conjugated hydroquinone. In case of 
urinary tract infection, pathogenic bacteria, such 
as Escherichia coli, can break down the urea. As 
a consequence urine becomes alkaline and this 
pH change causes the release of the free form 
hydroquinone which possesses antibacterial activity[6‑9].
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In cosmetics hydroquinone has been used as 
whitening agent, and recently it has been included 
by the European Commission in the Annex 
II of substances, which must not be part of the 
composition of cosmetic products because of their 
potential toxicity[10]. The use of herbal products as 
dietary supplements is growing nowadays. Illegal 
products can be confused with authorized ones so 
that uncontrolled intake of these compounds can 
cause a potential risk to human health. There is 
a large number of non licensed products which 
have been retrieved from the market because they 
could pose a clear risk to public health[10]. The 
uncontrolled use of bearberry in herbal free sale 
products can be dangerous since hydroquinone can 
cause liver and kidney toxicity after chronic oral 
administration[11‑13]. For this purpose, research was 
carried out to quantify in female rat plasma the 
main active ingredients of bearberry leaves and to 
assess arbutin and hydroquinone pharmacokinetic 
after administration of acute and subacute aqueous 
arbutin solutions. Although several methods for the 
extraction and quantification of these compounds from 
plasma have been reported, data on their validation 
are insufficient[14‑16].
For this reason the aim of our study was to develop 
and validate an extraction procedure and HPLC‑DAD 
method, according to international guidelines, in 
order to determine arbutin and its metabolite in rat 
plasma[17‑21].
MATERIALS AND METHODS
All chemical standards were of analytical grade. 
Arbutin (AR, purity≥96%) and hydroquinone (HQ, 
purity≥99.0%) were obtained from Sigma‑Aldrich 
(Milan, Italy); p‑chlorophenol was purchased from 
Acros organics (purity 99%; Geel, Belgium) and was 
used as internal standard (IS). Monohydrate citric acid 
(Phargam s.r.l., Varese, Italy purity 99.9%), disodium 
hydrogen phosphate (Rieldel‑deHaën purity 99%, 
Seelze, Germany), sodium hydroxide (J. T. Baker, 
Deventer Holland), ascorbic acid (Aldrich Germany, 
purity≥99%) were analytical grade reagents. Ethyl 
acetate (Panreac, Barcelona Espana), methanol and 
acetonitrile for HPLC were purchased from Aldrich 
(Milan, Italy). Isobutanol (Lab‑Scan, Dublin, Ireland) 
and n‑propanol (Carlo Erba, Milan, Italy) were 
analytical grade reagents. Distilled water (Milli‑Q 
gradient, Millipore, Vimidrone, Italy), for the mobile 
phase, was acidified with phosphoric acid (BDH 
Prolabo, England, purity≥85%). Tubes containing 
EDTA (BD Vacutainer System; UK) were used to 
collect rat blood samples. Supelco Visiprep and 
Supelco Visidry evaporation chamber (Sigma Aldrich, 
Milan, Italy) were used to evaporate extracted 
samples.
Other laboratory equipment included, calibrated 
automatic pipettes from Gilson (Villiers‑le‑Bel, 
France), Hettich centrifuge Mikro 22 R (Tuttlingen, 
Germany) with rotor Hettich centrifuge 1015 speed 
max 6000 rpm (12×35 g). The HPLC system, 
purchased from Perkin Elmer (Waltham, MA, USA) 
consisted of a pump (Biocompatible binary 250), 
a column oven (series 200), a vacuum degasser 
(series 200), an injector with a 20 μl sample loop 
(Rheodyne 7161), and a photodiode array detector 
(series 235C). The data were processed on a Perkin 
Elmer TotalChrom workstation system. The HPLC 
separation was performed on a Symmetry RP18 
Waters column (250×4.6 mm i.d.; 5 μm; Milford, 
MA, USA) equipped with a Waters Atlantis guard 
column (20×3.9 mm i.d.; 5 μm).
Preparation of standard stock solutions:
Stock standard solutions of arbutin and hydroquinone 
were prepared separately by dissolving a weighted 
amount of each reference standard in methanol, to 
obtain a final concentration of 10 mg/ml, and were 
stored at ‑20° until analysis.
Chromatographic conditions:
The HPLC analysis was performed on reversed‑phase 
high‑performance liquid chromatographic system. 
The substances were eluted with a mobile phase 
consisting of water at pH 3 with phosphoric acid 
(solvent A) and acetonitrile (solvent B) through a 
Fig. 1: Chemical structures of analytes.
(a) arbutin and (b) hydroquinone.
ba
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binary elution gradient as shown in Table 1. The 
flow‑rate was 1 ml/min, and arbutin and hydroquinone 
were detected at the wavelength of 230 nm, the 
column was kept at 25°.
Calibration curves:
Arbutin and hydroquinone solutions (10 mg/ml) were 
diluted with distilled water to obtain five working 
standard solutions with concentration ranging from 
1 to 20 μg/ml. The solutions were injected using a 
20 μl fixed loop system and chromatograms were 
recorded. A complete calibration curve was generated 
with each run for each of two substances. Each point 
of the curve was replicated six times, for each of 
two substances. Calibration curves were constructed 
by plotting average peak areas versus concentrations 
and regression equations were computed for both the 
substances.
Rat pharmacokinetic study:
The pharmacokinetic study was performed on 
100 female Wistar rats obtained from Charles River, 
Italy (200 g). The animals were housed and treated, 
by the Service for Biotechnology and Animal Welfare 
of Istituto Superiore di Sanità. According to the 
European and Italian Legislation the research protocol 
was approved on the 24th November 2004 by the 
Italian Ministry of Health with the decree number 
133/2004‑B. Rats were divided into 10 groups of 
5 animals each, and housed in metabolic cages. Rats 
were fed a standard diet (Mucedola, Milan, Italy) and 
water was administered ad libitum. The animal facility 
temperature was about 22° and light‑dark cycle was 
12 h.
Procedure of arbutin administration to rats:
Two aqueous arbutin solutions, 0.3 and 17 mg/ml, 
were prepared, respectively for the subacute 
toxicity and the acute toxicity studies. Fifty animals 
were used in the subacute toxicity study, and the 
remaining 50 rats in the acute toxicity study. 50 rats 
were used in the subacute toxicity study; 45 of them 
were administered twice by gavage 3 ml of 0.3 mg/ml 
aqueous arbutin solution and the remaining 5 were 
used as control and were administered always by 
gavage a blank solution. The other 50 rats were used 
in acute toxicity study; 45 of them were administered 
twice by gavage 3 ml of 17 mg/ml aqueous arbutin 
solution and the remaining 5 were used as control 
and were administered always by gavage a blank 
solution. The daily dose for each rat was 9 mg/kg for 
subacute toxicity study and 510 mg/kg for the acute 
toxicity study. The times for the sampling are shown 
in pharmacokinetic study section.
Plasma sample preparation:
The rat blood samples (1 ml) were obtained from 
posterior orbital venous plexus and were collected 
into tubes containing ethylenediaminetetraacetic acid 
(EDTA). The blood samples were then centrifuged at 
12 000 rpm for 5 min to separate plasma. The plasma 
was collected and stored at ‑20°.
Preparation of buffer solution:
Buffer solution was prepared with monohydrate citric 
acid and disodium hydrogen phosphate (10 mM) and 
pH was adjusted to 5 adding 2 N sodium hydroxide. 
L‑ascorbic acid solution (0.5 mg/ml), used as 
antioxidant agent, was dissolved in 100 ml of buffer 
solution. The buffer solution was used to prepare the 
Internal Standard work solution.
Preparation of standard solution:
Standard work solution of p‑chlorophenol (IS) was 
prepared dissolving a weighted amount of reference 
standard in methanol, to obtain a final concentration 
of 10 mg/ml, and was stored at ‑20° until analysis. 
An internal standard working solution (5 μg/ml) 
was prepared by diluting methanol p‑chlorophenol 
stock solution (IS) with the L‑ascorbic acid solution 
(0.5 mg/ml). This solution was used to prepare the 
plasma samples. A methanol solution, constituted of 
arbutin and hydroquinone (10 mg/ml), was diluted 
with distilled water at concentration of 0.1 mg/ml 
and then 50 µl were added to 450 µl blank plasma to 
obtain 500 µl of plasma.
Extraction procedure from plasma:
The extraction procedure was a simple liquid‑liquid 
extraction (LLE) with protein precipitation (PPT). 
The use of both PPT and LLE gives a clean sample. 
To identify the best extraction solution, several 
organic mixing solvents, described in (Table 2), were 
investigated. The highest recovery was obtained 
TABLE 1: ELUTION GRADIENT
Time (min) A (%) B (%)
0 95 5
10 80 20
35 10 90
Change of mobile phase composition during the elution
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with an organic solvent mixture constituted by 
ethyl acetate, isobutanol, propyl alcohol (60:30:10, 
v/v/v). 500 μl of plasma were added to 500 μl of 
internal standard solution (5 μg/ml); the mixture was 
vortex‑mixed for 2 min and then 2 ml of organic 
phase ethyl acetate, isobutanol, propyl alcohol 
(60:30:10; v/v/v) were added. The mixture was 
mechanical shaken for 2 min and then centrifuged 
for ten minutes at 10 000 rpm (6000 rcf) at 20°. The 
extraction procedure was repeated twice and the two 
upper organic phases were collected and evaporated 
to dryness. For the evaporation, a chamber under 
nitrogen gas at room temperature under vacuous was 
used. The dried residue was dissolved in 250 μl of a 
mixture of acetonitrile:water at pH 3 (5:95 v/v) and 
then one aliquot (20 μl) was used for HPLC analysis. 
In the same way the plasma spiked was processed to 
assess the recovery (fig. 2).
Method validation:
The method was validated according to the international 
guidelines for analytical methods[17‑21]. The parameters 
evaluated were identity, specificity, sensibility, linearity, 
limits of determination (LOD) and quantification (LOQ), 
trueness and precision as repeatability.
Pharmacokinetic study:
The new validated method was used to detect the 
concentration of both arbutin and hydroquinone in 
rat plasma, after acute and subacute administration 
of aqueous arbutin solution (17 and 0.3 mg/ml, 
respectively). Each plasma sample was collected at 
different times: 0, 0.5, 1, 2, 4, 8, 16, 24, 36 h and 
then was extracted according to the new developed 
and validated procedure. Sample concentrations 
of arbutin and hydroquinone in rat plasma were 
calculated from the formula:
STD
sample STD STDi
sample
STD STDi
Area × C AreaC = × ×DF
Area Area
Where, Areasample=peak area of sample; AreaSTD=peak 
area of standard; CSTD=arbutin or hydroquinone 
standard concentration; AreasampleSTDi=peak area 
of internal standard for sample; AreaSTDSTDi=peak 
area of internal standard for standard; DF=dilution 
factor.
RESULTS AND DISCUSSION
The confirmation of identity for arbutin and 
hydroquinone was obtained by comparing the 
retention times of the calibration solutions with 
those of test samples. In all cases the retention 
times were 4.74 min for arbutin, 7.95 min for 
hydroquinone and 26.06 min for p‑clorophenol 
(fig. 2). In addition, to guarantee the identity and 
specificity of the analytical method, the diode array 
detection was used to compare the spectrum of 
arbutin and hydroquinone in aqueous solution with 
the substances separated in rat samples. Linearity and 
sensibility was determined through the calibration 
curve. Calibration curve was studied in the following 
concentration range: 1‑20 μg/ml for both arbutin 
and hydroquinone. Calibration curve was replicated 
6 times and the mean of the determination coefficient 
was R2=0.9996±0.0006 and 0.9996±0.0002 for arbutin 
and hydroquinone, respectively. The sensibility was 
evaluated as the mean slope (ms) of 6 calibration 
curves: ms=11.7783±0.5342 for arbutin and 
ms=28.4417±0.6167 for hydroquinone (Table 3). 
As described in international guidelines[17], LOD 
and LOQ can be determined respectively as 3 and 
10 times the SD of repeated measurements of a blank 
matrix or as “mean+3 times the SD” and “mean+10 
times the SD” of repeated measurements of aqueous 
solution.
TABLE 2: ORGANIC MIXING SOLVENTS AT DIFFERENT 
RATIOS
Ethyl acetate (%) Isobutanol (%) n‑propanol (%)
100 0 0
90 10 0
80 20 0
70 30 0
60 40 0
60 10 30
Different solvent mixture ratios
Fig. 2: Chromatogram of rat blank plasma spiked with arbutin, 
hydroquinone and p-chlorophenol aqueous solution.
Arbutin, hydroquinone and p-chlorophenol with tR of 4.75, 7.95 and 
26.06 min respectively.
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We analyzed ten times a low level aqueous solution 
of each analytes under repeatability conditions. LOD 
was 0.0617 μg/ml for arbutin and 0.0120 μg/ml for 
hydroquinone. LOQ was 0.206 μg/ml for arbutin 
and 0.0400 μg/ml for hydroquinone (Table 3). 
Trueness was studied by analyzing, under repeatability 
conditions, spiked materials at one level of 
concentration (CM). Control material (CM) was 
analyzed and the mean recovery (Rm%) was 
estimated. Results are shown in Table 3.
Intraday and interday precision studies of aqueous 
solution of each analyte were carried out by 
estimating the corresponding responses 3 times 
on the same day and on 3 different days for 
the concentration of 0.01 mg/ml of arbutin and 
hydroquinone, respectively. Precision as repeatability 
was studied by repeated measurements (N=6) of 
the CM used for the trueness study. The results of 
repeatability are given in Table 3.
The application of the new method allowed to 
evaluate both arbutin and hydroquinone in an animal 
model treated with aqueous arbutin solution (fig. 3). 
The pharmacokinetics of two oral arbutin solutions 
were studied at nine different time points: 0, 0.5, 1, 2, 
4, 8, 16, 24, 36 h. The two pharmacokinetic profiles 
were represented in figs. 4 and 5.
A new extraction procedure and HPLC method for the 
arbutin and its metabolite hydroquinone in rat plasma 
were fully assessed and validated. The obtained data 
show good sensitivity, selectivity, linearity, precision 
and repeatability in the observed concentration range.
This validated method had allowed to assess the 
pharmacokinetic in animal model (Wistar rat) that 
could be fed with herbal products that contain the 
two main active ingredients arbutin and hydroquinone. 
The concentrations of arbutin and hydroquinone were 
determined in rat plasma to evaluate the potentially 
toxicity of commercially products containing these 
two substances.
TABLE 3: RESULTS OF REPEATABILITY AND RECOVERY
Parameter (units) Arbutin Hydroquinone
Linearity range (µg/ml) 1–20 1–20
Correlation coefficient (R2) 0.9996±0.0006 0.9996±0.0002
Sensibility (ms) 11.7783±0.5342 28.4417±0.6167
LOD (µg/ml) 0.0617 0.0120
LOQ (µg/ml) 0.206 0.0400
Mean (µg/ml) 10.7 10.6
SD 1.4 1.2
Repeatability (percentage of RSD) 13.33 11.67
Recovery (percentage of Rm) 93.40 92.94
n 6 6
Quantitative parameters for validation method. SD: standard deviation, 
LOD: limits of determination, LOQ: limits of quantification, RSD: relative 
standard deviation, Rm: mean recovery
Fig. 3: Chromatogram of rat plasma sample after administration of 
arbutin aqueous solution 17 mg/ml.
Arbutin and p-chlorophenol with tR of 4.75 and 26.06 min 
respectively.
Fig. 4: Arbutin plasma concentration-time profile after oral 
administration of a solution 17 mg/ml.
Pharmacokinetic curve after an acute administration of aqueous 
arbutin solution 17 mg/ml with Tmax 1 h and Cmax 0.1461 mg/ml.
Fig. 5: Arbutin plasma concentration-time profile after oral 
administration of a solution 0.3 mg/ml.
Pharmacokinetic curve after an subacute administration of aqueous 
arbutin solution 0.3 mg/ml with Tmax 2 h and Cmax 0.0316 mg/ml.
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In both the pharmacokinetics curves it was possible 
to observe that arbutin was quickly metabolized in 
the blood. The maximum arbutin concentration in the 
blood (Table 4) was not toxic for the rats and free 
of adverse events. As shown in figs. 4 and 5 and in 
the Table 4, the half‑life value of the acute toxicity 
analyses is much lower than the one of the subacute 
toxicity analyses; this may mean that a high 
concentration of arbutin in the blood induce an 
effective and rapid detoxification which leads to a 
good elimination of the substance.
The results showed only the presence of arbutin in 
the plasma, while there was no trace of hydroquinone 
that is probably present in other forms in plasma or is 
directly hydrolyzed in the urine.
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TABLE 4: ARBUTIN PHARMACOKINETIC PARAMETERS
Sample AUC (h·mg/ml) t1/2 (h) Cmax (mg/ml) tmax (h)
Arbutin 0.3 mg/ml 0.2591 43.0561 0.0316 2
Arbutin 17 mg/ml 0.3790 12.7066 0.1461 1
AUC (h·mg/ml) is the area under the plot of plasma concentration of drug against 
time after drug administration, t1/2 (h) the time required to reduce the plasma 
concentration to one half its initial value, Cmax (mg/ml) the mean maximum 
plasma concentration, tmax (h) time to reach the maximum plasma concentration
